An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

To­day on Post Hoc Live, Drew Arm­strong is joined by Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, ...

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top ...

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...